Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge (2007) - Drugs Forum
Drugs-Forum  
News Groups Blog Forum Chat Video Audio Images Documents Wiki Home
Go Back   Drugs Forum > VARIOUS DRUG RELATED TOPICS > Recovery and addiction
Register Tags Mark Forums Read

Notices

Recovery and addiction Support for coping with addiction and kicking the habit.

Reply
 
Thread Tools Display Modes
  #1  
Old 05-09-2008, 08:24
Jatelka's Avatar
Jatelka Jatelka is offline
Jatelka is back in a funk: The weekend aint so great!
Psychedelic Shepherdess
Moderator
 
Join Date: 16-10-2005
Location: United Kingdom
Age: 33
Posts: 5,025
Jatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond reputeJatelka is a true resource and beyond repute
Points: 18,312, Level: 19 Points: 18,312, Level: 19 Points: 18,312, Level: 19
Activity: 0% Activity: 0% Activity: 0%
Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge (2007)

A new entry has been added to File Archive

Description:
Tobacco Control 2007 Apr;16(2):138-42

Kotlyar M, Mendoza-Baumgart MI, Li ZZ, Pentel PR, Barnett BC, Feuer RM, Smith EA, Hatsukami DK.

OBJECTIVE: To compare nicotine pharmacokinetics and subjective effects of three new smokeless tobacco potential reduced exposure products (PREPs; Ariva, Revel and Stonewall) with moist snuff (Copenhagen) and medicinal nicotine (Commit lozenge). METHODS: 10 subjects completed a randomised, within-subject, crossover study. Subjects used one product for 30 min at each of the five laboratory sessions. Maximal nicotine concentration (Cmax) was determined and area under the concentration time curve (AUC) was calculated for a 90-min period (during use and 60 min after use). Nicotine craving, withdrawal symptoms and ratings of product effects and liking were measured during product use. RESULTS: Nicotine AUC and Cmax were higher for Copenhagen than for any other product (p<0.002) and higher for Commit than for either Ariva or Revel (p<0.001). Cmax for Commit was also higher than for Stonewall (p = 0.03). Craving was lowest during use of Copenhagen (p<0.03). Craving during use of Stonewall, Ariva and Commit was lower than during use of Revel (p<0.05). Withdrawal symptom score during use of Copenhagen was lower than during use of Revel (p = 0.009). Copenhagen scores were higher (p<0.005) than all other products in several measures of drug effects and liking (feel good effects, satisfaction, liking and desire for product, and strength of product). CONCLUSION: The new smokeless tobacco PREPs result in lower nicotine concentrations and equivalent or lower reductions in subjective measures compared with medicinal nicotine. Since health effects of PREPs are largely unknown, medicinal nicotine should be preferentially encouraged for smokers or smokeless tobacco users wishing to switch to lower-risk products.

To check it out, rate it or add comments, visit Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge (2007)
The comments you make there will appear in the posts below.
Reply With Quote
Reply

Bookmarks

Tags
nicotine effects, nicotine replacement, smokeless tobacco

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


Sitelinks: Site Functions:

All times are GMT +1. The time now is 04:20.


Copyright: Substance Information Network 2003 - 2009, All rights reserved